Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, open-label, non-randomized, single-center study to assess the pharmacokinetics, disposition, and biotransformation of [14C]-omecamtiv mecarbil a single intravenous or oral dose in healthy adult males

Next Previous
Trial Profile

Phase 1, open-label, non-randomized, single-center study to assess the pharmacokinetics, disposition, and biotransformation of [14C]-omecamtiv mecarbil a single intravenous or oral dose in healthy adult males

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 17 Sep 2021 Results assessing the excretion kinetics, excretion routes (feces and urine), mass balance and metabolites of Omecamtiv mecarbil after a single oral (PO) or intravenous (IV) dose of [14C]-Omecamtiv mecarbil, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
  • 27 May 2021 New trial record
  • 19 May 2021 Results published in the Drug Metabolism and Disposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top